Portugal-based Proteotype Diagnostics Unipessoal LDA on Thursday unveiled Alchemi, its proprietary data and clinical workflow platform being developed for Enlighten, the company's investigational blood-based multi-cancer test.

Enlighten measures changes in the body's response to tumour development using a laboratory kit. Alchemi is designed to standardise those measurements, govern analytical and machine-learning workflows and generate traceable, clinician-facing outputs. By supporting interoperability across laboratory and health-record systems through standards including HL7 FHIR and SNOMED CT, Alchemi is intended to reduce reliance on a single central testing facility and make Enlighten easier to integrate into local care pathways.

Alchemi is intended to provide shared digital infrastructure, through which multi-country datasets can be securely governed, analysed and translated into future clinical workflows. It will combine secure harmonisation of pseudonymised data generated across countries and laboratory environments; controlled development and validation of explainable machine-learning models; regulatory-compliant traceability; and a multilingual clinician portal for test ordering, result viewing and workflow management.

Alchemi's models are being designed to provide interpretable outputs, uncertainty measures and traceability of the data, model version and processing steps used to generate each result. A modular architecture will support jurisdiction-appropriate cloud deployment, with encryption, controlled access and comprehensive audit trails.

The 15-month development programme is supported by approximately EUR499,000 from the European Innovation Council's Pre-Accelerator. The grant will support machine-learning optimisation, multi-country data harmonisation, clinician-interface development, interoperability, cloud security, and medical-device and software lifecycle, quality and technical documentation.